trial · primary record
VRC-FLUMOS0116-00-VP
Influenza Prevention
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 45 |
| Primary completion | 2027-02-09 |
| Primary endpoint | Safety and tolerability of the FluMos-v2 (180 mcg) vaccine with ALFQ adjuvant administered to healthy adults at Day 0 and Week 16. |
| Registry ID | NCT06863142 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:20.349Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06863142
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.